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Abstract Objective: Despite many clinical studies, there is still uncertainty as to whether
venous material is superior to prosthetic materials for femoropopliteal reconstruction proximal
to the knee joint. A prospectively randomized clinical trial was designed to evaluate the effec-
tiveness of reversed saphenous vein in comparison with that of collagen impregnated woven
polyester prosthesis in above-knee arterial reconstruction.
Methods: In a 3-year period, 103 above-knee femoropopliteal bypass graft operations were
performed and followed in 85 patients (52 male, 33 female). The indication for operation
was severe claudication in 74 cases, rest pain in 7 cases, and ulceration in 4 cases. For the by-
pass graft, a reversed saphenous vein was used in each of 51 cases, and a collagen impregnated
woven polyester prosthesis was used in each of 52 cases. Preoperative risk factors were diabe-
tes (24%), a history of myocardial infarction (23%), and current status with respect to smoking
(74%). There was no hospital mortality; 5% of patients had minor postoperative complications.
Results: After 2 years of follow-up, the primary patency was 81% for saphenous vein and 67%
for collagen impregnated woven polyester prosthesis (PZ 0.065); the secondary patency was
81% for saphenous vein and 77% for collagen impregnated woven polyester prosthesis
(PZ 0.298). During this follow-up period of 2 years, we found no statistically significant differ-
ence in primary and secondary patency between saphenous vein and collagen impregnated
woven polyester prosthesis. We found no predictive factor for the occlusion of either bypass
graft.
Conclusion: The use of collagen impregnated woven polyester prosthesis above the knee is
a reasonable alternative in femoropopliteal bypass grafting that is associated with acceptable
short-term patency rates.
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Femoropopliteal bypass grafting has been shown to be an
effective form of treatment for arterial occlusive disease in
patients with severe claudication or critical ischemia. For
infrageniculate femoropopliteal bypass procedures, it has
been demonstrated that autologous saphenous veins pro-
vide the best possible conduit for bypass grafting.1,2 During
the last 10e15 years, many reports have published patency
rates for polyester (Dacron, Polythese, etc.), polytetra-
fluoroethylene (PTFE), and human umbilical vein for supra-
geniculate bypass graft procedures that are comparable to
the rate for autologous saphenous vein.3,4 Sparing the au-
tologous saphenous vein has the advantage that it can be
used later in more distal procedures and coronary bypass
graft procedures.5 Supported by early satisfactory results
with the use of collagen impregnated woven polyester
prosthesis as a suprageniculate bypass graft material,4,6e8
a prospective randomized trial was designed to evaluate
the effectiveness of reversed saphenous vein grafting in com-
parison with that of collagen impregnated woven polyester
bypass grafting in above-knee arterial reconstructions. The
aim of the present study was to show if there is a difference
in cumulative patency rates between saphenous vein and
collagen impregnated woven polyester bypass grafts, and
what are the consequences of bypass graft failure, also if
collagen impregnated woven polyester is used, the autolo-
gous vein will be available and usable for more distal proce-
dures later or not. The follow-up period of the investigation
will be 5 years. This article deals with the first 2-year
follow-up results of the study. We realize that differences
between the two graft types that are not apparent during
short-term follow-up might well be expected after a longer
period of follow-up.1,4,6,7,9
Patients and methods
The study was begun in January 2003 and carried out until
December 2005. All patients with severe claudication, de-
fined as claudication with a walking distance of less than
50 m, rest pain, or tissue loss undergoing femoropopliteal
reconstruction with the site of the distal anastomosis above
the knee joint, were eligible for the study. Above-knee graft-
ing was performed when the above-knee popliteal artery
was patent and suitable for anastomosis at operation. A pa-
tient was excluded if an arterial bypass graft procedure had
previously been performed in the same leg or if the greater
saphenous vein had been removed earlier. A history was
obtained for each patient; it included information on risk
factors related to arterial occlusive disease (diabetes, cardiac
history, and smoking habits). In every patient, an arteriogra-
phy and a hemodynamic profile by Doppler sonography
were obtained. Arteriography was performed by the trans-
lumbar route or transfemorally through the use of Seldinger
technique.
The popliteal and distal arteries were scored as open or
occluded.10 The hemodynamic profile comprised ankle
blood pressures and velocity profile of the common femo-
ral, popliteal, and distal arteries at the level of the ankle.
During the operation, the operating surgeon determined
the quality of the greater saphenous vein. If the vein wassuitable for bypass grafting (i.e., it had a diameter of
more than 4 mm proximally and 3 mm distally) then ran-
domization took place. Patients were not included in the
study when the vein was unsuitable for use as a bypass
graft. Either the reversed vein or a 6-mm collagen impreg-
nated woven polyester prosthesis (POLYTHESE IC, Perouse
Labs) was used. Preoperatively, an intravenous dose of 1 g
Cefalotin was administered. The operation was performed
after the administration of general or regional anesthesia.
Anastomoses were end to side, and continuous 6-0 Prolene
sutures, proximal to the common femoral artery and distal
to the popliteal artery, were used. Before arterial occlu-
sion, a bolus of 5000 IE of heparin was administered. Post-
operative anticoagulation therapy consisted of coumarin
during the first 6 months (with an international normalized
ratio between 2 and 4); this was followed by acetylsalicylic
acid (38 mg daily), considering the severe consequences of
occlusion of this type of bypasses.11 In our series we have
not seen any major complication of this therapy. Patients
were examined at 6 weeks, 3 months, 6 months, and 1
year and every year thereafter. Examination consisted of
a hemodynamic profile, a physical examination, and the
taking of a history. Graft occlusion was determined to
have developed if there was a drop in distal blood pressure
of more than 20% and a velocity profile by Doppler sonogra-
phy consistent with collateral flow in the distal popliteal
artery. If a collagen impregnated woven polyester bypass
graft occluded and the occlusion was detected within 7
days, a thrombectomy was performed. In all other cases,
a new operation was not considered necessary. In cases of
rest pain or necrosis, redo bypass graft procedures were
performed. The primary end point of the study was an
open or occluded bypass graft at the end of the second
year. Patients could be included in the study twice for pri-
mary operation on the left or the right limb. Analysis of the
primary end point was performed for each limb. A Cox pro-
portional hazard analysis was used to determine the influ-
ence of preoperative risk factors on patency of the bypass
graft and the t-test for comparing the operation mean
times. Also the Chi-square test was used for analyzing the
patency rates. The study protocol was approved by the
Institutional Review Board of Shahid Beheshti University of
Medical Sciences. Patient consent was obtained in all cases.
Results
Begun in January 2003, 103 bypass graft operations per-
formed in 85 patients who were followed up for 104 weeks
until December 2005 entered the study. The group con-
sisted of 49 males (57%) and 36 females (43%). The
indication for surgery was severe claudication in 74, rest
pain in 7, and necrosis in 4 cases. Preoperative risk factors
for vascular occlusive disease were diabetes (NZ 20; 24%),
previous myocardial infarction (NZ 19; 23%), and cigarette
smoking (NZ 63; 74%). The risk factors were equally di-
vided between those who received venous bypass grafts
and those who received collagen impregnated woven
polyester bypass grafts. Through the use of preoperative
arteriograms, the outflow arteries of all legs operated on
were classified according to the number of patent distal
arteries10 (Table 1). Reversed vein was used 51 times, and
Comparing vein with collagen impregnated woven polyester6-mm collagen impregnated woven polyester prostheses
were used 52 times. Of the patients with bilateral recon-
structions, 6 underwent bilateral construction with colla-
gen impregnated woven polyester grafts only, 3 with
venous grafts only, and 9 with both venous and collagen
impregnated woven polyester grafts. The operating time
was significantly longer for venous bypass grafts (mean,
105 min, S.D.Z 8.8) than for collagen impregnated woven
polyester grafts (mean, 73 min, S.D.Z 9.1) (PZ 0.002,
C.I.Z 95%). Superficial wound infection was seen in 4 cases
(collagen impregnated woven polyester grafts, 2; venous
grafts, 2). None of these infections necessitated reopera-
tion or resulted in the loss of the bypass graft. None of
the patients died in the hospital. After 1 year of follow-
up, 10 patients had died, 9 with patent bypass grafts and
1 with an occluded bypass graft. After 2 years, 12 patients
had died, 10 with open and 2 with occluded bypass grafts.
Of the remaining 73 cases, six were lost to follow-up. After
2 years, the overall primary patency rate was 75% (nZ 55).
Saphenous vein had a patency rate of 81% (nZ 36) and
collagen impregnated woven polyester had a patency rate of
67% (nZ 29; PZ 0.065; Table 2, Fig. 1). After reinterven-
tion, the secondary patency rate was 80% (vein, 81%; colla-
gen impregnated woven polyester, 77%; PZ 0.298; Table 3,
Fig. 2).
In 7 cases there was an occluded saphenous bypass graft.
We did not use thrombolytic therapy in our patients.
Reintervention was performed whenever the patient expe-
rienced severe disabling claudication or rest pain; in 4
instances it was necessary to perform a below-knee bypass
Table 1 Preoperative arteriography
No. of patent
tibial arteries
Vein,
N (%)
Occluded
vein, N (%)
Prosthesis,
N (%)
Occluded
prosthesis,
N (%)
3 29 (57) 3 (5) 20 (49) 7 (14)
2 14 (28) 4 (7) 18 (34) 5 (9)
1 8 (15) 1 (1) 8 (17) 1 (3)
Total 51 8 (15) 52 13 (26)
Table 2 Primary patency life table
Time
(wk)
Open
(n)
Occluded
(n)
LFU
(n)
Died
(n)
Patency
(%)
SEM
Vein 0 51 e e e 100 e
6 48 2 e 1 95 3.0
12 45 2 e 1 92 3.2
26 41 2 e 2 87 4.0
52 39 1 1 e 84 4.4
104 36 e 2 2 81 4.8
Prosthesis 0 52 e e e 100 e
6 51 e 1 e 98 1.3
12 44 4 e 2 91 3.3
26 38 2 1 3 84 4.2
52 33 5 e e 77 4.9
104 28 3 1 1 67 5.6
LFU, lost for follow-up.graft, always with autologous vein. In 1 case, after multiple
revisions the leg was lost nearly 2 years after the initial
operation because of ischemia. In 14 cases, there was an
occluded collagen impregnated woven polyester bypass
graft. Thrombectomy was performed 4 times; it was
successful in all cases. These bypass grafts were considered
‘‘secondary patent.’’ Below-knee bypass grafting was
performed with autologous vein. The Cox proportional
hazard analysis showed no significant predictive value for
the presence of diabetes mellitus, myocardial infarction, or
smoking with regard to occlusion of either venous or
collagen impregnated woven polyester bypass grafts
(Table 4). In addition, the number of open tibial arteries
did not have a predictive value with regard to occlusion
of the bypass graft (Table 1); this was true for both venous
and collagen impregnated woven polyester bypass grafts.
Discussion
The question of the best material for above-knee bypass
graft surgery continues to be controversial.3,4,12e14 How-
ever, most of the studies have been designed with either
no controls or historical controls or have been nonrandom-
ized investigations in which vein and collagen impregnated
woven polyester or PTFE was compared7,9,13; exception is
the multicenter trial by Veith et al.1 and a randomized trial
by Desiree et al.15 The current study differs from that of
the others in that 87% of patients in our series had claudica-
tion with a walking distance of less than 50 m, whereas all
of the patients in other studies had critical ischemia.1,15 In
the current prospectively randomized study, we found no
statistically significant difference in cumulative patency
rates between the venous and collagen impregnated woven
polyester bypass grafts up to 2 years after above-knee
bypass graft surgery, the primary patency rates being 83%
and 67% (PZ 0.065), respectively, and the secondary pa-
tency rates being 83% and 77%, respectively (PZ 0.298).
This could support the assumption that collagen impreg-
nated woven polyester prosthesis can be used with accept-
able patency for the treatment of occlusive disease of the
superficial femoral artery, although there is a clear trend
for venous bypass graft to perform better in the long run.
However, it should be acknowledged that a possible limita-
tion to this study is the relatively short follow-up. A statis-
tically significant difference in patency between vein and
collagen impregnated woven polyester might become
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Figure 1 Primary patency over time.
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112 A. Mohammadi Tofigh et al.Table 3 Secondary patency life table
Time (wk) Open (n) Occluded (n) Secondary open (n) LFU (n) Died (n) Patency (%) SEM
Vein 0 51 e e e 100 e
6 48 2 e 1 93 3.0
12 45 2 e 1 91 3.2
26 41 2 e 2 85 4.0
52 39 1 1 e 83 4.4
104 36 e 2 2 81 4.8
Prosthesis 0 52 e e e e 100 e
6 51 e e 1 e 98 1.1
12 46 4 e e 2 92 2.7
26 41 1 1 1 3 87 3.5
52 37 4 1 e e 81 4.2
104 32 2 2 1 1 77 4.5
LFU, lost for follow-up.evident after a longer time. The population of patients that
we operated on consisted largely of individuals with severe
claudication (87%). A consideration in the decision for oper-
ative intervention was the risk of complications. The num-
ber of major and minor complications was small in our
series and did not differ between the two types of bypass
graft. For our 103 operations, there was no hospital mortal-
ity, and there were no in-hospital occlusions of bypass
grafts. We therefore consider the above-knee bypass graft
a safe procedure, even in patients with disabling claudica-
tion. What were the consequences of bypass graft failure in
our study? In the group of 52 collagen impregnated woven
polyester bypass grafts, 14 occluded. Five of these patients
underwent successful thrombectomy, and in 6 a new oper-
ation was not considered necessary. Thus, in 21 occluded
bypass grafts in 103 cases, the veins that were ‘‘saved’’
were used 3 times. None of the patients needed the vein
for coronary bypass graft procedures within the follow-up
period. Accordingly, is it realistic to save the saphenous
vein for later, more distal procedures? We can see, even
in this small group of patients that the use of saphenous
vein does result in fewer occlusions and fewer reopera-
tions. Moreover, the need for coronary vein bypass graft
procedures decreases because of the use of mammary
arteries and percutaneous techniques. To be sure, there
are advantages to the use of collagen impregnated woven
polyester. First, the operating time is significantly smaller,
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Figure 2 Secondary patency over time.which could be beneficial when compromised patients are
being treated. Second, we found that none of the risk fac-
tors that are described in other studies had a negative influ-
ence on the patency of the collagen impregnated woven
polyester bypass grafts. Third, when thrombosis of the by-
pass graft is discovered early after occlusion, a thrombec-
tomy is a safe and simple procedure. Although there was
no significant difference in graft occlusion between the
two groups there were twice as many prosthetic grafts
occluded than vein grafts. However, in this study we found
a high though not statistically significant failure rate in the
group of collagen impregnated woven polyester bypass
grafts that had excellent three-vessel runoff. As for the
risk factors previously mentioned, we know from the earlier
studies that diabetes is such a factor. Prendiville et al.16
found that diabetes has a negative influence on the patency
of bypass grafts; others have found no such effect.4,9 In the
current study, there was no difference in patency due to
the influence of diabetes in either the prosthetic group or
the vein group. We also found that smoking did not nega-
tively influence the patency of the bypass graft, although
not everyone underwrites this finding,3,9,13,16 some au-
thors16 found that runoff did influence the patency of
bypass graft surgery. In the current study, there was no
significant difference between good and poor runoff for
either venous or prosthetic bypass grafts.3,4,6 A reason for
this finding could be the relatively proximal site of the
distal anastomosis. In the literature we can find different
results from the comparison between vein and prosthetic
materials, in the most recent ones Sala et al.17 found no dif-
ferences in long-term outcomes of above-knee femoropo-
pliteal artery bypass using autologous vein grafts or
Table 4 Relative risk for occlusion
Relative risk Confidence limits
Sex 0.66 0.33e1.32
Age 1.00 0.97e1.04
Diabetes 1.82 0.91e3.63
Myocardial infarction 0.62 0.26e1.48
Smoking 1.28 0.64e2.55
Cox proportional hazard analysis.
Comparing vein with collagen impregnated woven polyester prosthesis 113prosthetic materials, but Klikert et al.18 reject this hypoth-
esis and conclude that autologous vein is better than pros-
thetic materials, our findings in short time are concurrent
with the first group, although in long term the results can
change. Most researches have not found any significant dif-
ference between Dacron and PTFE as graft materials.19,20,21
The current study would seem to justify answering the
question of whether collagen impregnated woven polyester
can be used for above-knee femoropopliteal bypass grafting
as follows: it can be used safely in compromised patients
and those with a short life expectancy.8,22 However, to an-
swer the question of whether collagen impregnated woven
polyester should be the first choice in every patient, follow-
up for this prospective study must be completed within 5
years.
Ethical statements
Prosthetic materials and analogous vein are both routinely
used for the femoropopliteal bypasses and other researches
had shown effectiveness of the two methods. This study
was planned for a more precise evaluation of the results in
long term. Many recent researches had shown that none of
these methods have dangerous complications for the
patients if used appropriately.
Our aims and methods were completely explicated for
the patients and their consent was obtained in all cases.
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